Content about Fenofibrate

April 23, 2014

Dr. Reddy's Labs on Wednesday announced the launch of fenofibrate capsules, USP in 43-mg and 130-mg strengths. The drug is the generic version of Antara (fenofibrate) capsules.

HYDERABAD, India — Dr. Reddy's Labs on Wednesday announced the launch of fenofibrate capsules, USP in 43-mg and 130-mg strengths. The drug is the generic version of Antara (fenofibrate) capsules.

The Antara capsules brand and generics had U.S. sales of approximately $74 million MAT for the most recent 12 months ending February 2014, according to IMS Health. Dr. Reddy's fenofibrate capsules, USP 43-mg is available in bottle counts of 30; 130-mg are available in bottle counts of 30 and 90.

 

July 18, 2013

The Food and Drug Administration has approved a cholesterol drug made by Par Pharmaceutical Cos., the drug maker said Thursday.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a cholesterol drug made by Par Pharmaceutical Cos., the drug maker said Thursday.

Par announced the approval of generic fenofibric acid delayed-release capsules in the 45-mg and 135-mg strengths. The drug is used to reduce triglycerides and increase "good" high-density lipoprotein cholesterol.

The drug is a generic version of AbbVie's Trilipix, which has sales of about $554 million per year, according to IMS Health.

 

July 15, 2013

Mylan has launched a generic drug for treating cholesterol problems, the company said Monday.

PITTSBURGH — Mylan has launched a generic drug for treating cholesterol problems, the company said Monday.

Mylan announced the launch of generic fenofibric acid delayed-release capsules in the 45-mg and 135-mg strengths.

The drug is a generic version of Abbott's Trilipix, designed for use in combination with statin drugs and diet to reduce triglycerides and increase high-density lipoprotein or "good" cholesterol.

Various versions of the drug had sales of about $553.6 million during the 12-month period that ended in March, according to IMS Health.

May 17, 2013

Mylan has launched a generic drug for treating cholesterol, the company said.

PITTSBURGH — Mylan has launched a generic drug for treating cholesterol, the company said Friday.

Mylan announced the launch of fenofibrate tablets in the 48 mg and 145 mg strengths. The drug is used to reduce so-called "bad" low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B while increasing "good" high-density lipoprotein cholesterol in adults with primary hyperocholesterolemia or mixed dyslipidemia.

February 25, 2013

Mylan has begun shipping a generic drug for cholesterol, the company said Monday.

PITTSBURGH — Mylan has begun shipping a generic drug for cholesterol, the company said Monday.

Mylan said a subsidiary had started shipping fenofibrate capsules in the 43-mg and 130-mg strengths. The drug is a generic version of Lupin Atlantis Holdings Antara, used in combination with diet to reduce elevated bad cholesterol and other blood lipids and increase beneficial HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia.

November 21, 2012

Lupin Pharmaceuticals has launched a generic drug for cholesterol disorders, the company said.

BALTIMORE — Lupin Pharmaceuticals has launched a generic drug for cholesterol disorders, the company said.

Lupin announced the launch of fenofibrate tablets in the 48-mg and 145-mg strengths. The drug is used to treat hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia.

The drug is a generic version of Abbott's Tricor, which had sales of $1.26 billion during the 12-month period ended in June, according to IMS Health.

November 1, 2011

Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

HAYWARD, Calif. — Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

The latest sales figures represented a $12.2 million increase over third quarter 2010, while profits were $4.2 million higher.

June 6, 2011

The Food and Drug Administration has found manufacturing issues at a plant owned by generic drug maker Impax Labs, the drug maker said Monday.

HAYWARD, Calif. — The Food and Drug Administration has found manufacturing issues at a plant owned by generic drug maker Impax Labs, the drug maker said Monday.

August 26, 2010

According to a recent study published in the science journal PloS One, eating grapefruit could...

July 22, 2010

In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow...

WINSTON-SALEM, N.C. In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

May 2, 2010

Drug maker Abbott has sued a Watson Pharmaceuticals subsidiary over its attempt to market a...